By Colin Kellaher

 

Bristol-Myers Squibb Co. (BMY) on Tuesday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a flat-dosing schedule for its cancer drug Opdivo in adults with the skin cancer melanoma.

The New York biopharmaceutical company said the committee's positive opinion covers two-week and four-week flat dosing of Opdivo for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

The European Commission, which generally follows the CHMP's recommendations, will review the decision for final action, Bristol-Myers said.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 24, 2019 09:10 ET (13:10 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Bristol Myers Squibb Charts.